Press Releases Year None2020201920182017 March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version March 12, 2020 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PDF Version February 27, 2020 MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors PDF Version February 18, 2020 SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference PDF Version January 13, 2020 Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma PDF Version January 6, 2020 SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference PDF Version December 9, 2019 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) PDF Version November 12, 2019 SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights PDF Version October 24, 2019 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) PDF Version September 24, 2019 European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version
March 12, 2020 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PDF Version
February 27, 2020 MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors PDF Version
February 18, 2020 SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference PDF Version
January 13, 2020 Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma PDF Version
January 6, 2020 SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference PDF Version
December 9, 2019 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) PDF Version
November 12, 2019 SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights PDF Version
October 24, 2019 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) PDF Version
September 24, 2019 European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma PDF Version
